Ready 8-Ks
6
Latest filing
October 20, 2026, 7:00 AM ET
Top materiality
0.75
Event mix
other_material ×3 · earnings ×2 · other ×1
Sentiment
2 pos · 0 neg · 4 neu
Recent 8-K filings for ODTX
Highest-materiality recent filing
Odyssey OD-001 Phase 2a UC induction: 27% clinical remission at 20mg BID; primary endpoint met
- Primary endpoint met: mean 2.4-point reduction in modified Mayo score at Week 12 across 56 efficacy-evaluable patients (p<0.001).
- 20 mg BID (n=41): clinical remission 27%, clinical response 61%, symptomatic remission 49%; 10 mg BID (n=15): 20%, 40%, 27%.
-
Odyssey OD-001 Phase 2a UC induction: 27% clinical remission at 20mg BID; primary endpoint met
Primary endpoint met: mean 2.4-point reduction in modified Mayo score at Week 12 across 56 efficacy-evaluable patients (p<0.001).
-
Odyssey Therapeutics Q1 net loss $38.3M; pro-forma cash $464M; positive OD-001 data
Cash and securities $175.7M at Mar 31, 2026; pro-forma cash $464.4M after IPO net proceeds of $288.7M.
-
Private placement of 1,388,889 shares of common stock at $18.00 per share for total proceeds of $25,000,002.
Materiality & sentiment trend
Max materiality 0.75 · Median 0.57 · Most common event other_material